Henagliflozin

Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes. In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.
Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose [cotransporter 2] which leads to a reduction in blood glucose levels.
In a 26-week placebo-controlled trial of type 2 diabetics, telomere length significantly lengthened, the Insulin-like [growth factor 1|IGF-1 pathway] was inhibited, and immune system function was improved in the henagliflozin group compared to the placebo group.